

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of the claims in the application.

**Listing of Claims**

Claims 1-36 (cancelled)

Claim 37 (currently amended): A method of reducing a stimulus-induced airway response[[],] selected from the group consisting of airway constriction, bronchospasm, airway hyperreactivity, eosinophil accumulation in bronchial walls, an increase in airway resistance, or combinations thereof, said method comprising:

- administering by inhalation to a subject at risk of experiencing [[a]] said stimulus-induced airway response a therapeutically effective amount of an agent selected from the group consisting of:
  - (a) human calcitonin gene-related peptide (human CGRP);
  - (b) rat CGRP;
  - (c) the diacetoamidomethyl cysteine form of (a); and
  - (d) the diacetoamidomethyl cysteine form of (b);

wherein said agent is administered prior to said airway response and wherein said method results in no or substantially no haemodynamic side effects.

Claim 38 (previously presented): The method of claim 37 wherein said stimulus is selected from the group consisting of a non-specific stimulus and exposure to an irritant.

Claim 39 (previously presented): The method of claim 38 wherein said irritant is selected from the group consisting of an allergen and an agonist.

Claim 40 (cancelled)

Claim 41 (previously presented): The method of claim 37 wherein said airway response is selected from the group consisting of early or late phase responses induced by said stimulus.

Claim 42 (previously presented): The method of claim 37 wherein said airway comprises the lower segments of the tracheobronchial tree.

Claim 43 (previously presented): The method of claim 37 wherein said agent is selected from the group consisting of human CGRP and rat CGRP.

Claim 44 (previously presented): The method of claim 37, wherein said agent is selected from the group consisting of the diacetoamidomethyl cysteine form of human CGRP and the diacetoamidomethyl cysteine form of rat CGRP.

Claim 45 (previously presented): The method of claim 37 wherein said agent is selected from the group consisting of human  $\alpha$  CGRP and rat  $\alpha$  CGRP.

Claim 46 (previously presented): The method of claim 37, wherein said agent is selected from the group consisting of the diacetoamidomethyl cysteine form of human  $\alpha$  CGRP and the diacetoamidomethyl cysteine form of rat  $\alpha$  CGRP.

Claims 47-48 (cancelled)

Claim 49 (previously presented): The method of claim 37, wherein said agent is administered such that it contacts the respiratory epithelium of said subject.

Claim 50 (previously presented): The method of claim 37, wherein said agent has a purity of at least about 95 to 98%.

Claim 51 (previously presented): The method of claim 37, wherein said agent is dispersed within a composition comprising a pharmaceutically acceptable excipient, and/or a liquid or solid carrier.

Claim 52 (currently amended): The method of claim 51, wherein said composition is formulated ~~for administration by inhalation~~ as an aerosol or dry powder.